DiaMedica Therapeutics Inc.
DMAC
Positions held
Your positionsDMAC isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $431.94M | Enterprise value | $388.63M | Trailing P/E | — | Forward P/E | -9.91 |
| PEG | — | Price / book | 11.27 | Beta | 0.91 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -114.6% | ROA | -64.1% | Debt / equity | 0.00 |
| Current ratio | 6.72 | Free cash flow | -$17.65M | Analyst recommendation | strong_buy | Mean target | $15.50 |
| 52w high | $10.42 | 52w low | $5.25 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$10.1M | -$10.0M | -$8.7M | -$8.6M | -$7.7M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$10.5M | -$10.5M | -$9.2M | -$9.0M | -$8.0M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — |
| Net income | -$32.8M | -$24.4M | -$19.4M | -$13.7M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$34.4M | -$26.7M | -$21.3M | -$14.0M |
Headlines — positive tone
• [OK · fundamentals] All You Need to Know About DiaMedica Therapeutics (DMAC) Rating Upgrade to Buy
News
2026-09-02 · DiaMedica Therapeutics to Participate in Upcoming September Investor Conferences
2026-08-26 · Wall Street Analysts Think DiaMedica Therapeutics (DMAC) Could Surge 129.97%: Read This Before Placing a Bet
2026-08-18 · DiaMedica (DMAC) Q2 2026 Earnings Call Transcript
2026-08-13 · All You Need to Know About DiaMedica Therapeutics (DMAC) Rating Upgrade to Buy
2026-08-11 · DiaMedica Therapeutics Inc (DMAC) (Q2 2026) Earnings Call Highlights: Promising Preeclampsia ...
2026-08-11 · DiaMedica Therapeutics Inc. Q2 2026 Earnings Call Summary
2026-08-11 · DiaMedica Therapeutics Q2 Earnings Call Highlights
2026-08-10 · DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights
2026-08-04 · DiaMedica Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Business Update August 11, 2026
2026-08-03 · DiaMedica Therapeutics (DMAC): BioTech with Breakthrough Potential
2026-07-17 · DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Price (daily)
Full chart · RSI · MACD · patterns